MA47472A - Anticorps - Google Patents
AnticorpsInfo
- Publication number
- MA47472A MA47472A MA047472A MA47472A MA47472A MA 47472 A MA47472 A MA 47472A MA 047472 A MA047472 A MA 047472A MA 47472 A MA47472 A MA 47472A MA 47472 A MA47472 A MA 47472A
- Authority
- MA
- Morocco
- Prior art keywords
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1414270.7A GB201414270D0 (en) | 2014-08-12 | 2014-08-12 | Antibodies |
GB201422614 | 2014-12-18 | ||
GBGB1507541.9A GB201507541D0 (en) | 2015-05-01 | 2015-05-01 | Antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
MA47472A true MA47472A (fr) | 2019-12-18 |
Family
ID=53836090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA047472A MA47472A (fr) | 2014-08-12 | 2015-08-12 | Anticorps |
Country Status (25)
Country | Link |
---|---|
US (2) | US11149090B2 (fr) |
EP (2) | EP3552665A3 (fr) |
JP (1) | JP6654187B2 (fr) |
KR (1) | KR102443258B1 (fr) |
CN (2) | CN106573981A (fr) |
AU (1) | AU2015303164B2 (fr) |
CA (1) | CA2957146A1 (fr) |
CL (1) | CL2017000335A1 (fr) |
CO (1) | CO2017001317A2 (fr) |
CR (1) | CR20170096A (fr) |
DK (1) | DK3180087T3 (fr) |
EA (1) | EA201790339A1 (fr) |
EC (1) | ECSP17008984A (fr) |
ES (1) | ES2725463T3 (fr) |
IL (1) | IL250512B (fr) |
MA (1) | MA47472A (fr) |
MX (1) | MX2017001864A (fr) |
NI (1) | NI201700015A (fr) |
NZ (1) | NZ729270A (fr) |
PE (1) | PE20170680A1 (fr) |
PH (1) | PH12017500229A1 (fr) |
SG (1) | SG11201701070WA (fr) |
SV (1) | SV2017005380A (fr) |
UA (1) | UA119783C2 (fr) |
WO (1) | WO2016023960A1 (fr) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG194701A1 (en) | 2011-04-29 | 2013-12-30 | Apexigen Inc | Anti-cd40 antibodies and methods of use |
DK2953634T3 (da) | 2013-02-07 | 2021-08-30 | Massachusetts Gen Hospital | Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler |
AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
US10344090B2 (en) | 2013-12-12 | 2019-07-09 | Shanghai Hangrui Pharmaceutical Co., Ltd. | PD-1 antibody, antigen-binding fragment thereof, and medical application thereof |
MY189018A (en) | 2015-11-18 | 2022-01-19 | Merck Sharp & Dohme | Pd1 and/or lag3 binders |
WO2017106061A1 (fr) | 2015-12-14 | 2017-06-22 | Macrogenics, Inc. | Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation |
KR102410778B1 (ko) * | 2016-05-13 | 2022-06-21 | 더 제너럴 하스피탈 코포레이션 | 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체 |
WO2017220988A1 (fr) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anticorps multispécifiques pour l'immuno-oncologie |
EP3484922A1 (fr) * | 2016-07-14 | 2019-05-22 | Genmab A/S | Anticorps multispécifiques dirigés contre cd40 et cd137 |
EP3504239A1 (fr) | 2016-08-25 | 2019-07-03 | H. Hoffnabb-La Roche Ag | Dosage intermittent d'un anticorps anti-csf-1r en combinaison avec un agent d'activation de macrophages |
WO2018078620A1 (fr) | 2016-10-25 | 2018-05-03 | Urogen Pharma Ltd. | Traitements immunomodulateurs de cavités corporelles |
AU2017353852A1 (en) * | 2016-11-02 | 2019-05-23 | Apexigen, Inc. | Anti-CD40 antibodies in combination and methods of use |
CN110072553B (zh) | 2016-12-22 | 2023-09-15 | 豪夫迈·罗氏有限公司 | 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗 |
ES2902670T3 (es) * | 2017-01-13 | 2022-03-29 | Taizhou Hanzhong Biopharmaceutics Inc | Anticuerpo monoclonal contra PD-1 y aplicaciones del mismo |
EP3589324A1 (fr) * | 2017-03-03 | 2020-01-08 | Janssen Biotech, Inc. | Co-thérapie comprenant un inhibiteur de csf-1r à petite molécule et un anticorps agoniste qui se lie spécifiquement au cd40 pour le traitement du cancer |
US20200237860A1 (en) | 2017-08-31 | 2020-07-30 | Multimmune Gmbh | Hsp70 based combination therapy |
KR20210038839A (ko) * | 2018-03-13 | 2021-04-08 | 히버셀, 인크. | 베타 글루칸 및 cd40 효능제 조합 면역요법 |
US20210386856A1 (en) * | 2018-06-12 | 2021-12-16 | Biontech Us Inc. | Combination therapy with neoantigen vaccine |
WO2019241730A2 (fr) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires |
AU2019383548A1 (en) | 2018-11-23 | 2021-06-24 | Strike Pharma Ab | Bi-specific conjugates |
AU2019389354A1 (en) * | 2018-11-30 | 2021-07-15 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-CD40 antibody, antigen binding fragment and pharmaceutical use thereof |
MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
CN113939535A (zh) * | 2019-05-28 | 2022-01-14 | 詹森生物科技公司 | 提供抗cd40抗体的安全施用的方法 |
EP4027998A1 (fr) | 2019-09-09 | 2022-07-20 | Basilea Pharmaceutica International AG | Combinaisons pharmaceutiques comprenant un furazanobenzimidazole et un agoniste de cd40 pour une utilisation dans le traitement de maladies néoplasiques |
EP4076434A1 (fr) | 2019-12-17 | 2022-10-26 | Flagship Pioneering Innovations V, Inc. | Polythérapies anticancéreuses ayant des inducteurs de désassemblage cellulaire dépendant du fer |
EP4083210A1 (fr) * | 2019-12-27 | 2022-11-02 | Interoligo Corporation | Composition immunothérapeutique anticancéreuse destinée à traiter un cancer |
GB202008003D0 (en) | 2020-05-28 | 2020-07-15 | Quine Medical Ab | Anti-CD40 antibody |
CN116096906A (zh) | 2020-06-29 | 2023-05-09 | 旗舰创业创新五公司 | 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途 |
WO2022036495A1 (fr) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Co-stimulateurs de cellules présentatrices d'antigène de lymphocytes et leurs utilisations |
US20220325287A1 (en) | 2021-03-31 | 2022-10-13 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
WO2023278641A1 (fr) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Cellules immunitaires modifiées pour favoriser la thanotransmission de phényléthanolamines et leurs utilisations |
WO2023064878A1 (fr) * | 2021-10-15 | 2023-04-20 | The Rockefeller University | Combinaison d'anticorps anti-cd40 et d'il-15 pour le traitement du cancer |
WO2023247050A1 (fr) | 2022-06-23 | 2023-12-28 | Alligator Bioscience Ab | Polythérapies |
WO2024077191A1 (fr) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Molécules d'acide nucléique codant pour des trif et des polypeptides supplémentaires et leur utilisation dans le traitement du cancer |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
WO2001083755A2 (fr) | 2000-04-28 | 2001-11-08 | La Jolla Institute For Allergy And Immunology | Anticorps humains anti-cd40, et leurs procedes de production et d'utilisation |
PT1341909E (pt) | 2000-12-12 | 2005-10-31 | Alligator Bioscience Ab | Metodo para a evolucao molecular in vitro da funcao de proteina |
EP2011802A3 (fr) | 2001-04-27 | 2009-04-15 | Kyowa Hakko Kirin Co., Ltd. | Anticorps monoclonal anti-CD40 |
AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
US20040110226A1 (en) | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
US7262012B2 (en) | 2002-05-17 | 2007-08-28 | Alligator Bioscience Ab | Method for in vitro molecular evolution of protein function using varied exonuclease digestion in two polynucleotide populations |
CN101001872A (zh) * | 2004-04-16 | 2007-07-18 | 宏观基因有限公司 | FcγRIIB-特异性抗体及其使用方法 |
RU2006141632A (ru) | 2004-04-27 | 2008-06-10 | Новартис Вэксинес Энд Дайэгностикс, Инк. (Us) | Антагонистические моноклональные анти-cd40-антитела и способы их применения |
CA2607147C (fr) | 2005-05-09 | 2018-07-17 | Ono Pharmaceutical Co., Ltd. | Anticorps monoclonaux humains pour mort programmee 1 (mp-1) et procedes pour traiter le cancer en utilisant des anticorps anti-mp-1 seuls ou associes a d'autres immunotherapies |
CA2609269C (fr) | 2005-05-26 | 2014-08-05 | Seattle Genetics, Inc. | Anticorps anti-cd40 humanises et procedes d'utilisation |
GB0620894D0 (en) * | 2006-10-20 | 2006-11-29 | Univ Southampton | Human immune therapies using a CD27 agonist alone or in combination with other immune modulators |
AU2009206506B2 (en) | 2008-01-23 | 2013-01-10 | Xencor, Inc. | Optimized CD40 antibodies and methods of using the same |
US20110311525A1 (en) | 2008-08-29 | 2011-12-22 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Delivery of a cd40 agonist to a tumor draining lymph node of a subject |
WO2013019906A1 (fr) | 2011-08-01 | 2013-02-07 | Genentech, Inc. | Procédés de traitement du cancer à l'aide d'antagonistes se liant à l'axe pd-1 et inhibiteurs de mek |
GB201115280D0 (en) * | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
WO2014121099A1 (fr) * | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Protéine de fusion agoniste des cd40 ox40 et ses utilisations |
EP3082857B1 (fr) | 2013-12-20 | 2018-07-25 | F. Hoffmann-La Roche AG | Thérapie de combinaison avec un anticorps anti-ang2 et un agoniste de cd40 |
TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
RS60753B1 (sr) | 2015-04-17 | 2020-10-30 | Bristol Myers Squibb Co | Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba |
AR104809A1 (es) | 2015-05-29 | 2017-08-16 | Abbvie Inc | Anticuerpos anti-cd40 y usos de los mismos |
EA035268B1 (ru) | 2015-06-29 | 2020-05-22 | Бристол-Маерс Сквибб Компани | Антитела к cd40 |
EP3313886A1 (fr) | 2015-06-29 | 2018-05-02 | The Rockefeller University | Anticorps anti-cd40 présentant une activité agoniste renforcée |
-
2015
- 2015-08-12 CN CN201580043161.1A patent/CN106573981A/zh active Pending
- 2015-08-12 MA MA047472A patent/MA47472A/fr unknown
- 2015-08-12 NZ NZ729270A patent/NZ729270A/en unknown
- 2015-08-12 SG SG11201701070WA patent/SG11201701070WA/en unknown
- 2015-08-12 JP JP2017507739A patent/JP6654187B2/ja active Active
- 2015-08-12 DK DK15750051.3T patent/DK3180087T3/da active
- 2015-08-12 ES ES15750051T patent/ES2725463T3/es active Active
- 2015-08-12 KR KR1020177005821A patent/KR102443258B1/ko active IP Right Grant
- 2015-08-12 US US15/329,402 patent/US11149090B2/en active Active
- 2015-08-12 CA CA2957146A patent/CA2957146A1/fr active Pending
- 2015-08-12 CR CR20170096A patent/CR20170096A/es unknown
- 2015-08-12 EP EP19161728.1A patent/EP3552665A3/fr active Pending
- 2015-08-12 EP EP15750051.3A patent/EP3180087B1/fr active Active
- 2015-08-12 MX MX2017001864A patent/MX2017001864A/es unknown
- 2015-08-12 WO PCT/EP2015/068598 patent/WO2016023960A1/fr active Application Filing
- 2015-08-12 CN CN202111420044.6A patent/CN114099671A/zh active Pending
- 2015-08-12 PE PE2017000203A patent/PE20170680A1/es unknown
- 2015-08-12 EA EA201790339A patent/EA201790339A1/ru unknown
- 2015-08-12 AU AU2015303164A patent/AU2015303164B2/en active Active
- 2015-08-12 UA UAA201701452A patent/UA119783C2/uk unknown
-
2017
- 2017-02-07 SV SV2017005380A patent/SV2017005380A/es unknown
- 2017-02-07 PH PH12017500229A patent/PH12017500229A1/en unknown
- 2017-02-08 IL IL250512A patent/IL250512B/en unknown
- 2017-02-09 NI NI201700015A patent/NI201700015A/es unknown
- 2017-02-09 CL CL2017000335A patent/CL2017000335A1/es unknown
- 2017-02-10 CO CONC2017/0001317A patent/CO2017001317A2/es unknown
- 2017-02-10 EC ECIEPI20178984A patent/ECSP17008984A/es unknown
-
2021
- 2021-09-15 US US17/475,592 patent/US20210403589A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR21C1030I2 (fr) | Conjugué anticorps anti-her2-médicament | |
MA47472A (fr) | Anticorps | |
MA45004A (fr) | Anticorps spécifiques anti-wt1-hla | |
DK3344654T3 (da) | Anti-lag-3-antistoffer | |
MA53297A (fr) | Anticorps anti-icos | |
DK3556777T3 (da) | Multispecifikke antistofkonstrukter | |
DK3191517T3 (da) | Krydsreaktive siglec-antistoffer | |
DK3134402T3 (da) | 4-amino-imidazoquinolinforbindelser | |
DK3183051T3 (da) | Væske-til-luftmembranenergivekslere | |
DK3119885T3 (da) | Antistof-fynomer-konjugater | |
DK3211743T3 (da) | Ø-til-netværk-omskiftningsfremgangsmåde | |
DK3222714T3 (da) | Phytasemutanter | |
DK3350218T3 (da) | Polyomavirus-neutraliserende antistoffer | |
NL301172I2 (nl) | Lonapegsomatropine | |
DK3119396T3 (da) | Muscarinreceptoragonister | |
DK3148591T3 (da) | Nanopartikel-lægemiddelkonjugater | |
DK3006072T3 (da) | Karadgang | |
MA42843A (fr) | Anticorps anti-cd115 | |
DK3110442T3 (da) | Modificerede meningokok-fhbp-polypeptider | |
MA51554A (fr) | Anticorps il-6 améliorés | |
DK3174483T3 (da) | Hyporørkonstruktion | |
DK3250593T3 (da) | Anti-transthyretin-antistoffer | |
DE112015001664A5 (de) | Betätigungsaktuator | |
DK3092003T3 (da) | Hidtil ukendt anti-netrin-1-antistof | |
DK3154587T3 (da) | Konjugater omfattende et anti-egfr1-antistof |